This molecule inhibited angiogenesis in vitro through downregulation of the expression of vascular endothelial growth factor receptor 2 (VEGFR2) on endothelial cells and blocking the secretions of vascular endothelial growth factor A (VEGFA) and interleukin 6 (IL-6) from highly vascularized cancer cells (A498, HuH-7, and NCI-H727) [51]. Here, KDR is linked to cancer.